Allogenic CD19-targeting CAR-γδT Cell Therapy in r/r NHL

Non Hodgkin's Lymphoma Clinical Trial

Official title:

Allogenic CD19-targeting Chimeric Antigen Receptor γδT Cells Therapy in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05554939
• Other study ID #: CHN-PLAGH-BT-072
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: December 11, 2022
• Est. completion date: December 31, 2026

Study information

• Verified date: March 2024
• Source: Chinese PLA General Hospital
• Contact: Weidong Han, Ph.D
• Phone: +86-010-55499341
• Email: hanwdrsw[@]sina.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

CD19-CAR-γδT cell therapy is a cellular immunotherapy targeting CD19 to perform CAR modification on allogeneic γδT cells. In this study, a second-generation anti-CD19 CAR prototype was constructed, bearing murine FMC63 single-chain variant fragment (scFv) together with intracellular 4-1BB co-stimulatory and CD3ζ signaling domains linked by a CD8α sequence comprising the hinge and transmembrane domains. The cells were derived from the patient's relative donors or unrelated healthy donors. Human leukocyte antigen (HLA) -mismatched or partially matched or full matched are acceptable. The upgraded version of the CAR-γδT product that has been validated for resistance to alloreactive T cell killing will be used in this study after March 20th, 2024. This is a single center, prospective, open-label, single-arm, phase 1/2 study. A total of around 30 patients with relapsed or refractory (r/r) B-cell non-Hodgkin's lymphoma (NHL) will be enrolled in the study and receive allogeneic CD19-CAR-γδT cell infusion. Phase 1 (n=9 to 12) is dose escalation part, and phase 2 (n=15 to 20) is expansion cohort part. The primary objective of this study was to evaluate the safety and efficacy of allogeneic CD19-CAR-γδT cell therapy in patients with r/r B-cell NHL.

Description:

Phase 1 (dose escalation) In phase 1, 9-12 subjects will be enrolled. Subjects will receive 3 doses of CD19-CAR- γδ T cell therapy (2 × 10^6 cells/kg、6× 10^6 cells/kg、1.8 × 10^7 cells/kg) increases from low dose to high dose according to the "3 + 3" principle: 1. Three patients were enrolled in the lowest dose group. 2. Subsequent patients were enrolled according to the following rules: 1. If the incidence of dose limiting toxicity (DLT) was 0/3, 3 patients were enrolled in the next high-dose group. 2. If the incidence of DLT was 1/3, 3 patients were enrolled at the same dose; If the incidence of DLT was 1/3 + 0/3, 3 patients were enrolled in the next high-dose group. If the incidence of DLT was 1/3 + 1/3, this dose was defined as maximum tolerated dose (MTD); If the incidence of DLT was 1/3 + 2/3 or 1/3 + 3/3, the previous dose was MTD. 3. If the incidence of DLT was 2/3 or 3/3, the previous dose was MTD. To ensure the safety of the subjects, the first subject in each dose group was observed for at least 28 days after the cell infusion. If no DLT occurred, the remaining two subjects could be enrolled and treated at the same dose level. The safety data of all subjects in each dose group until day 28 should be reviewed and tolerated before proceeding to the next dose group trial. No dose escalation was allowed for the same subject during the trial. If a subject drop out during the observation period due to non-DLT reasons, new subjects should be enrolled to make up for the number of subjects who drop out. Phase 2 (expansion cohort) In phase 2, 15 to 20 subjects will be enrolled and receive CD19-CAR-γδ T cell infusion at dose of RP2D, which will be determined based on the MTD, occurrence of DLT, the obtained efficacy results, pharmacokinetics/pharmacodynamics and other data according to the phase 1. Objectives The primary objectives of the phase 1 were to evaluate the tolerability, safety, and determine recommended phase 2 dose (RP2D). The primary purpose of the phase 2 study was to evaluate the efficacy.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: December 31, 2026
• Est. primary completion date: December 31, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria for patients:

1. Age 18-75 (inclusive).

2. Patients with histologically confirmed CD19-positive B-cell NHL, including the

following types defined by the World Health Organization (WHO) 2016:

• Diffuse large B-cell lymphoma not otherwise specified (DLBCL-NOS), including Activated B-cell type (ABC)/Germinal center B-cell type(GCB);
• Primary mediastinal (thymic) large B-cell lymphoma (PMBCL);
• Transformed follicular lymphoma (TFL);
• High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements (HGBCL);
• Follicular lymphoma (FL);
• Mantle cell lymphoma (MCL) (pathologically confirmed, with documentation of monoclonal B cells that have a chromosome translocation t(11;14)(q13;q32) and/or overexpress cyclin D1);
• Marginal zone lymphoma (MZL), including nodal or splenic marginal zone B-cell lymphoma and mucosa-associated lymphoid tissue (MALT) lymphoma.

3. Relapse after treatment with =2 lines systemic therapy for all the above disease types, or refractory disease for aggressive types (DLBCL-NOS, PMBCL, TFL and HGBCL). Relapse disease is defined as disease progression after last regimen. Refractory

disease is defined as no CR to first-line therapy:

• PD as best response to first-line therapy, or
• SD as best response after at least 4 cycles of first-line therapy (eg,4 cycles of R-CHOP), or
• PR as best response after at least 6 cycles and biopsy-proven residual disease or disease progression = 6 months of therapy, or
• Refractory post-autologous stem cell transplant (ASCT) i. Disease progression or relapsed less than or equal to 12 months of ASCT (must have biopsy proven recurrence in relapsed individuals) ii. If salvage therapy is given post-ASCT, the individual must have had no response to or relapsed after the last line of therapy.

4. Individuals must have received adequate prior therapy:

• For MCL, prior therapy must have included:
• Anthracycline or bendamustine-containing chemotherapy and
• Anti-CD20 monoclonal antibody (unless investigator determines that tumor is CD20-negative) and
• Bruton's tyrosine kinase inhibitor (BTKi)
• For other types, prior therapy must have included:
• Anti-CD20 monoclonal antibody (unless investigator determines that tumor is CD20-negative) and
• Anthracycline containing chemotherapy regimen.
• For individual with transformed FL must have relapse or refractory disease after transformation to DLBCL.

5. The estimated survival time is over 3 months.

6. The Eastern Cooperative Oncology Group (ECOG) score is 0-2.

7. According to Lugano response criteria 2014, there should be at least one evaluable tumor focus. Evaluable tumor focus was defined as that with the longest diameter of intranodal focus > 1.5cm, the longest diameter of extranodal focus > 1.0cm assessed by computed tomography (CT) or magnetic resonance imaging (MRI).

8. Subjects must be willing to undergo either excised or large-needle lymph node or tissue biopsy, or provide formalin-fixed paraffin-embedded (FFPE) tumor tissue block or freshly cut unstained slides.

9. Functions of important organs meet the following requirements: Echocardiography showed left ventricular ejection fraction =50%. Serum creatinine =1.5 × upper limit of normal range (ULN) or endogenous creatinine clearance =45mL/min (cockcroft-gault formula); Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =3 times ULN, Total bilirubin =1.5× ULN; Pulmonary function: =CTCAE grade 1 dyspnea and oxygen saturation of blood (SaO2) =91% in indoor air environment.

10. Blood routine (normal values shall not be obtained with growth factors, and hemocytopenia caused by lymphoma invasion of bone marrow is not subject to conditions below): hemoglobin (Hgb) =80g/L, neutrophil count=1×10^9/L, platelet (PLT) =75×10^9/L.

11. Pregnancy tests for women of childbearing age shall be negative; Both men and women agreed to use effective contraception during treatment and during the subsequent 1 year.

12. Toxicity from previous antitumor therapy = grade 1 (according to CTCAE version 5.0) or to an acceptable level of inclusion/exclusion criteria (other toxicities such as alopecia and vitiligo considered by the investigator to pose no safety risk to the subject).

13. No obvious hereditary diseases.

14. Able to understand the requirements and matters of the trial, and willing to participate in clinical research as required.

15. Informed consent must be signed.

Exclusion Criteria for patients:

1. During the screening period, there was central nervous system (CNS) invasion or a history of clinically significant central nervous system diseases, such as epilepsy and cerebrovascular diseases.

2. Women who are pregnant or breastfeeding, or who do not agree to use effective contraception during treatment and during the subsequent 1 year.

3. History of allogeneic hematopoietic stem cell transplantation, or organ transplantation.

4. History of other malignancies that have not been in remission.

5. Patients with primary immunodeficiency or autoimmune diseases requiring immunosuppressive therapy.

6. Received radiotherapy within 3 months before enrollment.

7. Received immunotherapy drugs within 4 weeks before enrollment, such as anti-programmed death 1 (PD-1) antibody, anti-programmed death ligand 1 (PD-L1) antibody, CD19/CD3-bispecific antibody, and so on.

8. Patients who received any immunocellular therapy within 6 months before enrollment.

9. Confirmed evidence showing positiveness of anti-CD19 scFv reaction in patient serum.

10. Patients who participated in other clinical trials within 4 weeks prior to enrollment.

11. Uncontrolled infectious diseases or other serious illnesses, including but not limited to infections [e.g., human immunodeficiency virus (HIV) infection or acute or chronic active hepatitis B (HBV) or C (HCV) infection], congestive heart failure, unstable angina, arrhythmias, or that pose an unpredictable risk in the opinion of the attending physician.

12. The presence of uncontrollable serous membrane fluid, such as massive pleural effusion or ascites.

13. A history of stroke or intracranial hemorrhage within 3 months prior to enrollment.

14. Major surgery or trauma occurred within 28 days prior to enrollment, or major side effects have not been recovered.

15. Received allogeneic cell therapy within 6 weeks prior to enrollment, such as donor lymphocyte infusion.

16. History of allergies to any of the ingredients in cell products.

17. Conditions in which a known mental or physical illness interferes with cooperation with the requirements of the study or disrupts the results or interpretation of the results and, in the opinion of the therapeutic investigator, makes the patient unfit for study participation.

18. There is the situation that the researcher's judgment will interfere with the whole study participation; Situations where there is significant risk to the subject; Or interferes with the interpretation of research data.

19. Inability to understand or unwillingness to sign informed consent.

20. Researchers believe that other reasons are not suitable for clinical trials.

Related Conditions & MeSH terms

• Lymphoma
• Lymphoma, Non-Hodgkin
• Non Hodgkin's Lymphoma

Intervention

Biological:
• Allogenic CD19-CAR-?dT cell
Phase 1 dose escalation (3+3) : dose 1 (2 × 10^6 cells/kg) , dose 2 (6 × 10^6 cells/kg), dose 3 (1.8 × 10^7 cells/kg); Phase 2 : dose of RP2D.

Drug:
• Fludarabine
Intravenous fludarabine 30~50 mg/m^2/day on days -5, -4, and -3.
• Cyclophosphamide
Intravenous cyclophosphamide 500~1000 mg/m^2/day on days -5, -4, and -3.

Locations

Country	Name	City	State
China	Biotherapeutic Department, Chinese PLA General Hospital	Beijing
China	School of phamaceutical, Tsinghua University	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Chinese PLA General Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Relationship between infusion dose of CD19-CAR-?dT cells and efficacy	The relationship between the number of CD19-CAR-?dT cells, copy number, cytokines level, GVHD response, and anti-tumor effect of CD19-CAR-?dT cells was analyzed. Peripheral blood was collected at the day of infusion (day 1), day 4, day 7, day 11, day 14, day 28, at least once every month after 28 days, at least once every three months after half a year, and at least once every six months after a year. The number of CAR-?dT cells was detected by flow cytometry, and the copy number was detected by quantitative PCR (qPCR).	12 months
Other	Dynamics characteristic of CAR-?dT cells and key molecular and cellular mechanisms of B-cell tumor resistance in vivo after infusion	The dynamic changes of the number and copy number of CAR-?dT cells in patients after CD19-CAR-?dT treatment were analyzed. The peak, expansion pattern and continuous expansion time of CAR-?dT cells in vivo were studied, and the evolution of CAR-?dT cells in vivo was summarized. To analyze the expansion of CAR-?dT cells in peripheral blood of patients with primary or acquired resistance after CD19-CAR-?dT treatment, the evolution of CD19 antigen and other changes at the cellular or molecular level after treatment, and to summarize the key cellular and molecular mechanisms of resistance.	12 months
Primary	Phase 1: Incidence of Adverse Events (AEs)	AE is defined as any adverse medical event from the date of lymphodepletion to 12 months after CD19-CAR-?dT cells infusion. Among them, cytokine release syndrome (CRS) and immune cell-associated neurotoxicity syndrome (ICANS) were graded according to American Society for Transplantation and Cellular Therapy (ASTCT) criteria, graft-versus-host disease (GVHD) according to criteria defined by the Mount Sinai Acute GVHD International Consortium. Other AEs were graded according to common terminology criteria for adverse events (CTCAE) v5.0.	12 months
Primary	Phase 1: Incidence of Dose-Limiting Toxicities (DLTs)	DLT was defined as CD19-CAR-?dT cells-related events with onset within first 28 days following infusion: Grade 3 aGVHD that does not resolve to Grade 1 or 2 within 7 days, with the exception of isolated skin involvement aGVHD; Grade 4 CRS or grade 3 CRS that does not resolve to grade 2 or lower within 2 weeks; Grade 3 ICANS lasting for =7 days or Grade 4 ICANS; Any other Grade =4 and Grade 3 AE related to the ATHENA CAR-T that lasts for =14 days, except hematology toxicity.	First infusion date of CD19-CAR-?dT cells up to 28 days
Primary	Phase 1: Maximum tolerated dose (MTD)	MTD is defined as the highest dose level of less than or equal to 2 DLT among the 6 subjects finally determined.	12 months
Primary	Phase 1: Recommended phase 2 dose (RP2D)	The recommended dose for phase 2 was determined through phase 1 study.	12 months
Primary	Phase 2: Best objective Response Rate	The incidence of complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD), or unevaluable (UE) as the best response to treatment assessed by investigators and based on the Lugano 2014 assessment criterion.	12 months
Secondary	Phase 2: Overall Survival (OS)	OS is defined as the time from CD19-CAR-?dT cells infusion to the date of death. Subjects who have not died by the analysis data cutoff date will be censored at their last contact date.	12 months after the first infusion of CD19-CAR-?dT cells
Secondary	Phase 2: Progression Free Survival (PFS)	PFS is defined as the time from the CD19-CAR-?dT cells infusion date to the date of disease progression assessed by investigators and based on the Lugano 2014 assessment criterion, or death any cause. Participants not meeting the criteria for progression by the analysis data cutoff date were censored at their last evaluable disease assessment date.	12 months after the first infusion of CD19-CAR-?dT cells
Secondary	Phase 2: Time to response (TTR)	TTR is defined as the time from CD19-CAR-?dT infusion to first assessed CR or PR by investigators and based on the Lugano 2014 assessment criterion.	12 months
Secondary	Phase 2: Duration of Response (DOR)	DOR is defined as the date of their first CR or PR (which is subsequently confirmed) to PD assessed by investigators and based on the Lugano 2014 assessment criterion for r/r B-cell NHL, or death regardless of cause.	12 months
Secondary	Pharmacokinetics: Number and copy number of CD19-CAR-?dT cells (phase 1 and phase 2)	Number and copy number of CD19-CAR-?dT cells were assessed by number in peripheral blood. Blood samples were collected before and one year after cell infusion (until CD19-CAR-?dT cells were not detected for two consecutive times) to detect the number and copy number of CD19-CAR-?dT cells, and to evaluate the pharmacokinetics of CD19-CAR-?dT.	12 months
Secondary	Pharmacokinetics: Persistence of CD19-CAR-?dT (phase 1 and phase 2)	Persistence of CD19-CAR-?dT cell assessed by number in peripheral blood.	12 months
Secondary	Pharmacodynamics: Peak level of cytokines in serum (phase 1 and phase 2)	The cytokines mainly include interleukin-2 (IL-2 ), IL-6, IL-8, IL-10, tumor necrosis factor-a (TNF-a), C reactive protein (CRP), ferritin. Peak was defined as the maximum post-baseline level of the cytokine.	Up to 28 days after infusion
Secondary	Immunogenicity: Proportion of subjects with anti drug antibody (ADA) (phase 1)	ADAs include anti-donor ?dT antibody or anti-CD19 CAR single-chain variable fragment antibody.	12 months